
    
      The CRYSTAL study is a prospective, multi-center, randomized (1:1), single-blinded and
      controlled, investigational device exemption trial to test the non-inferiority of MiStent to
      commercially available "everolimus" drug eluting stents (Xience and Promus stents).

      Patients with coronary artery disease (CAD) that qualify for percutaneous coronary
      intervention (PCI) with stenting will be screened per the protocol inclusion and exclusion
      criteria.
    
  